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Background: It is unclear whether more timely cancer diagnosis brings favourable outcomes, with much of the previous evidence,
in some cancers, being equivocal. We set out to determine whether there is an association between time to diagnosis, treatment
and clinical outcomes, across all cancers for symptomatic presentations.
Methods: Systematic review of the literature and narrative synthesis.
Results: We included 177 articles reporting 209 studies. These studies varied in study design, the time intervals assessed and the
outcomes reported. Study quality was variable, with a small number of higher-quality studies. Heterogeneity precluded definitive
findings. The cancers with more reports of an association between shorter times to diagnosis and more favourable outcomes were
breast, colorectal, head and neck, testicular and melanoma.
Conclusions: This is the first review encompassing many cancer types, and we have demonstrated those cancers in which more
evidence of an association between shorter times to diagnosis and more favourable outcomes exists, and where it is lacking. We believe
that it is reasonable to assume that efforts to expedite the diagnosis of symptomatic cancer are likely to have benefits for patients in
terms of improved survival, earlier-stage diagnosis and improved quality of life, although these benefits vary between cancers.
Symptomatic diagnosis of cancer is important and has been the
subject of considerable innovation and intervention in recent years
to achieve timelier and earlier-stage diagnosis (Emery et al, 2014);
the English National Awareness and Early Diagnosis Initiative has
made a major contribution to this effort (Richards and Hiom,
2009; Richards, 2009a). We know that patients value timely
diagnostic workup, and that later stage at diagnosis is one of the
contributory factors to poor cancer outcomes (Richards, 2009b).
However, it is less clear whether more timely cancer diagnosis
brings favourable outcomes. Systematic reviews in breast cancer
reported that delays of 3–6 months were associated with lower
survival (Richards et al, 1999), and in colorectal cancer it was
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concluded that there were no associations between diagnostic
delays and survival and stage (Ramos et al, 2007, 2008; Thompson
et al, 2010). Other reviews have been published for gynaecological
cancers (Menczer, 2000), bladder (Fahmy et al, 2006), testicular
(Bell et al, 2006), lung (Jensen et al, 2002; Olsson et al, 2009),
paediatric cancers (Brasme et al, 2012a, b) and head and neck
cancers (Goy et al, 2009; Seoane et al, 2012), all with equivocal
findings. No review to date has undertaken this work in a range of
different cancer types.
Longer time to diagnosis may be detrimental in several ways: a
more advanced stage at diagnosis, poorer survival, greater
disease-related and treatment-related morbidity and adverse
psychological adjustment. Conversely, harm may be caused
by earlier detection of cancers without improving survival
(lead-time), and detection of slow-growing tumours not needing
treatment (over-diagnosis) (Esserman et al, 2013). A scoping
review, undertaken before the review reported here, showed that
observational studies in many cancers reported no association or
an inverse relationship between longer diagnostic times and
better outcomes (Neal, 2009). We therefore undertook a
systematic review of the literature aiming to determine whether
there is an association between time to diagnosis, treatment and
clinical outcomes, across all cancers for symptomatic presenta-
tions only.
MATERIALS AND METHODS
We undertook a systematic review in two phases. The original
review was conducted in 2008–10, and the literature from
inception of databases to February 2010 was searched; the update
was conducted in 2013–14, and the literature from February 2010
to November 2013 was searched. The original review did not
include breast or colorectal cancer (because of prior systematic
reviews); however, these were included in the update (as we knew
of more papers published in these cancers). The review adhered to
principles of good practice (Egger et al, 2001; NHS Centre for
Reviews and Dissemination, 2001). Reporting is in line with the
PRISMA recommendations (Moher et al, 2009).
A search strategy was developed for Medline (Figure 1) and
adapted for other search sources. A range of bibliographic
databases were searched for relevant studies. These were as follows:
 MEDLINE, MEDLINE in-process, EMBASE, CINAHL, PsychINFO
 Cochrane Central Register of Controlled Trials, Database of
Abstracts of Reviews of Effects, Cochrane Database of Systematic
Reviews, Health Technology Assessment Database, NHS Eco-
nomic Evaluation database.
Reference lists of studies included in this and previous reviews were
hand-searched for relevant studies.
One reviewer screened the titles and abstracts of all records
for relevance, and assessed potentially relevant records for
inclusion. A second reviewer checked the decisions; disagreements
were resolved by discussion or, if necessary, by a third reviewer. A
study or analysis was included in the review if it:
 Reported patients with symptomatic diagnosis of primary cancer
(screen- and biomarker-detected cancers were excluded).
 Primarily aimed to determine the association of at least one time
interval to diagnosis or treatment (patient, primary care,
secondary care or a combination), allowing assessment against
accepted definitions (Weller et al, 2012). The outcomes of
interest were any measure of survival or mortality; any
description of stage, including extent or severity of disease at
diagnosis and response to treatment; or quality of life.
 Was available as full text in English.
Data extraction for all included studies was done by one
researcher and checked by another. We extracted data relating to
the following:
 Characteristics of included studies: study aim, population,
location, setting, definitions of time intervals, data collection
methods used and outcome measures.
 Clinical outcomes: included the measure of association, associa-
tions of intervals with outcomes and reported interpretation.
1. Exp neoplasms/
2. (time adj4 diagnos$).ti,ab.
3. (time adj4 consult$).ti,ab.
4. (time adj4 treat$).ti,ab.
5. (time adj4 refer$).ti,ab.
6. (time adj4 present$).ti,ab.
7. (time adj4 interv$).ti,ab.
8. (time adj4 therap$).ti,ab.
9. or/2–8
10. (delay$ adj4 diagnos$).ti,ab.
11. (delay$ adj4 consult$).ti,ab. 
12. (delay$ adj4 treat$).ti,ab. 
13. (delay$ adj4 refer$).ti,ab. 
14. (delay$ adj4 present$).ti,ab. 
15. (delay$ adj4 interv$).ti,ab. 
16. (delay$ adj4 therap$).ti,ab. 
17. (delay$ adj4 seek).ti,ab. 
18. (delay$ adj4 care).ti,ab. 
19. (delay adj4 detect*).ti,ab. 
20. or/10–19 
21. (interval adj4 diagnos$).ti,ab. 
22. (interval adj4 consult$).ti,ab. 
23. (interval adj4 treat$).ti,ab. 
24. (interval adj4 refer$).ti,ab. 
25. (interval adj4 present$).ti,ab. 
26. (interval adj4 therap$).ti,ab. 
27. or/21–26 
28. (late adj4 diagnosis).ti,ab. 
29. (late adj4 detect*).ti,ab. 
30. (late adj4 present$).ti,ab. 
31. or/ 28–30 
32. (duration adj4 symptom$).ti,ab. 
33. Wait$ time$.mp. 
34. 9 or 20 or 27 or 31 or 32 or 33 
35. 1 and 34 
36. limit 35 to (english language and humans and yr="2010 -current")
37. Editorial or letter or practice guideline or biography or case reports or clinical
conference or comment or consensus development conference or NIH or
guideline or newspaper article or patient education handout 
38. Cells[Mesh] or Mass screening[Mesh] or genetic screening[Mesh]) or pregnancy[Mesh]
39. Pharmaceutical preparations[Mesh]
40. Chemical. hw
41. #37 or #38 OR # #39 or #40
42. 36 NOT 41
The original search strategy was found to be too sensitive and produced a large number 
of non-relevant references. This was revised and refined to capture all relevant articles.
The number of databases searched was also more extensive for the original search, 
but on investigation, it was evident that all included articles had been found on databases 
subsequently chosen for the updated review.
Figure 1. Search strategy (medline).
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 Bias assessment: we envisaged at the outset that there would be
considerable variation between included studies in terms of
study design, and that many may be of poor quality (Neal, 2009).
We therefore considered that the assessment of methodological
quality was especially important. However, at that time, there
were no widely accepted checklists for checking the quality of
prognostic studies, and there was little empirical evidence to
support the importance of individual criteria, or study features,
in affecting the reliability of study findings (Altman, 2001).
Hence, we decided against the use of quality scoring, and to use a
checklist instead of a scale. Judgements on the risk of bias were
made according to a number of domains, using a generic list of
questions within each domain (Figure 2), based primarily on a
framework for assessing prognostic studies (Altman, 2001). For
the updated review, and being aware of more recent literature on
assessing the quality of prognostic studies, we decided to keep
Sample representativeness: Is the sample representative of the relevant cancer patient population? The population may be quite specific,   
typified by age, stage, ethnicity or other factors.
Yes: only if this is clearly reported 
Can’t tell: if it’s reported in an ambiguous way 
Not reported: if it doesn’t say 
If none of the above, please qualify with free text (this may be a majority of studies)
Characteristics reporting: Was the reporting of participant characteristics complete? 
Yes: only if this is clearly and fully reported
Can’t tell: is if it’s reported in an ambiguous way
Not reported: if it doesn’t say
If none of the above, please qualify with free text (this may be the majority of studies, for example those who just give age and gender) 
Representativeness of participants: Were participants who participated (or whose data were used) representative of the sample from which  
they (or it) were sourced?
Yes: only if this is clearly and fully reported
Can’t tell: is if it’s reported in an ambiguous way
Not reported: if it doesn’t say
Not applicable: if all of the sample participated, for example, database study
If none of the above, please qualify with free text 
Bias minimisation in measurement of symptom duration: Were steps taken (as stated by the investigators) to minimise and check for, biases
and inaccuracies introduced owing to the method used for measurement of symptom duration?
Yes: if clear evidence of this, please list information as free text: MANDATORY 
No: if no evidence of this
Can’t tell: if unclear (this includes where results may be reported but no mention in methods)
Independent variable assessment: Was the assessment symptom duration (explanatory variable) conducted independent of the assessment
of the outcome variable?
Yes: if reported as done
No: if clearly reported that same researcher did it
Not reported: if it doesn’t say
Not applicable: if the method does not require this to be done, for example, database study
A priori definition of outcome variable: Was the outcome variable specified/defined a priori?
Yes
No 
Appropriate definition of outcome variable: Was the outcome variable clearly defined?
Yes: for example, type of stage, type of survival, not necessary to enter detail
No: anything other than yes
Multivariate analysis: Was multivariate analysis conducted?
Yes
No 
Prognostic adjustment: Was adjustment for important prognostic factors conducted as part of the analysis?  
Yes: if clear evidence of this, (for example: performance status, age, smoking, co morbidity), please qualify with free text MANDATORY
No: if no evidence of this
Can’t tell: if unclear (this includes where results may be reported but no mention in methods), please qualify with free text MANDATORY 
Outlier adjustment for symptom duration: Was adjustment for outliers conducted as part of the analysis?
Yes: if clear evidence of this, please qualify with free text MANDATORY 
No: if no evidence of this
Not applicable:  for example if there were no symptom durations greater than 2 years or less for more quickly diagnosed cancers 
Can’t tell: if unclear (this includes where results may be reported but no mention in methods), please qualify with free text MANDATORY
Confounder adjustment: Was adjustment for confounders (identified in advance of the study) conducted as part of the analysis? 
Yes: if clear evidence of this, please qualify with free text MANDATORY 
No: if no evidence of this
Can’t tell: if unclear (this includes where results may be reported but no mention in methods), please qualify with free text MANDATORY  
We also identified studies (update only 2010–13) that addressed the so-called ‘waiting time paradox’ (see text).
Figure 2. Bias assessment tool.
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the original questions, as they were in line with the new Quality
in Prognosis Studies tool (Hayden et al, 2006, 2013). In addition,
in the update, we identified studies that addressed the so-called
‘waiting time paradox’ (Crawford et al, 2002), which were likely
to be of higher analytical quality. These were defined as follows:
‘articles that undertake an analysis or sub-analysis that speci-
fically includes or excludes patients who are either diagnosed
very quickly (e.g., within 4–8 weeks, although this will vary
between cancers), or have very poor outcomes (e.g., deaths
within a short time after diagnosis, e.g., within 4–8 weeks).’
Agreement on inclusion in this subset of articles was done by
two members of the study team. This is the ‘paradox’ caused by
the inclusion of patients with aggressive disease who invariably
present early and have poor outcomes as a result of the
aggressive disease, and is a form of confounding by indication.
 Clinical outcomes: the measure of association, associations of
intervals with outcomes and interpretation.
We planned to undertake meta-analysis if there were sufficient
homogenous studies reporting a similar outcome measure and the
same interval for an individual cancer. Narrative synthesis was
undertaken otherwise.
RESULTS
Study selection. The number of studies screened, assessed for
eligibility, included and reasons for exclusion are shown in
Figure 3. Of the 1036 records identified for full-text review, 177
articles, reporting 209 studies, met the inclusion criteria and
entered the narrative synthesis. A number of the articles reported
data on more than one cancer, or more than one interval.
Data collection in the included studies
Definition of time intervals. There were 15 different intervals
reported in the included studies (Figure 4).
Clinical and psychological outcomes. Data collection for the
outcome measures was predominantly retrospective review of
medical records (using a variety of the following: clinical,
pathological, histological and imaging) and cancer registries.
Patient questionnaires were used for studies with psychological
outcomes. Most studies used various measures of survival (or
mortality) and/or stage as outcome measures.
Bias assessment. The bias assessment demonstrates the mixed
quality of the studies (Supplementary Online Material). On a positive
note, the characteristics and representativeness of the samples were
reported in most articles, the definitions and appropriateness of time
intervals were well reported and many studies undertook multi-
variable analysis. However, the representativeness of the samples was
not reported in many articles, and few studies undertook confounder
adjustment, prognostic adjustment or attempted bias minimisation.
Only seven of the articles made an attempt to address the waiting
time paradox (Tørring et al, 2011, 2012, 2013; Brasme et al, 2012a, b;
Elit et al, 2013; Gobbi et al, 2013; Pruitt et al, 2013). Hence, most
studies failed to address the premise of confounding by indication–
 
 
 
 
 
Records identified for all cancer sites by electronic
searching after de-duplication
(n = 193 077) 
Records rejected on the basis of title and/or
abstract as not relevant to this review
(n = 191 376) 
Records identified through other
sources (searching bibliographies,
reference lists of reviews)
(n = 41) 
Records assessed for
retrieval
(n = 1742)
Breast and colorectal cancer records
published up to March 2010
(n =706)*
Full-text articles retrieved for detailed
evaluation and assessment for inclusion
(n = 1036)
Documents that could not be
assessed for inclusion because:
unable to retrieve from
library loans
(n =7) 
Full-text articles excluded, with
reasons:
not English language, not full text
peer reviewed paper, opinion
piece, no relevant outcome data,
does not report at least one time
interval to diagnosis or
treatment, case reports,
guidelines/methodology, not
primary symptomatic cancer,
study protocol, duration data not
linked to outcome, review,
(n = 852) 
Studies (listed below by cancer site) included in qualitative
synthesis (n =209) Articles (n =177)   
Breast (n =13), lung (n = 20), gastric (n =11), oesophageal (n = 4),
gastro-oesophageal (n =2), pancreatic (n = 5), hepatocellular (n = 2),
colorectal (n =19), prostate (n = 6), renal (n = 2), bladder (n =7),
testicular (n = 16), upper tract urothelial (n =2), cervical (n= 3),
endometrial (n = 9), ovarian (n = 8), head and neck (n = 27),
brain/CNS (n = 1), melanoma (n = 11), non-melanoma skin (n = 3),
CTYA (n =19), leukaemia (n = 3), lymphoma (n = 5),
myeloma (n = 2), connective tissue (n = 6), carcinoid (n =1),
thyroid (n = 1), multi-site (n = 1)
Figure 3. Flow diagram. *Of those breast and colorectal cancer records published up to March 2010 (n¼706) assessed for retrieval, 330 were
retrieved and assessed for inclusion but were not included in the evaluation, as systematic reviews on these cancers had been recently published.
The follow-up review, covering the period March 2010 to October 2013, included both breast and colorectal cancers in the qualitative synthesis.
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that is, the relationship between the diagnostic pathway (and hence
the time interval) and prognosis.
Study characteristics. Of the 177 articles included, there were a
total of 401 760 participants, with a range of 13 to 147 682 in
individual study size (Supplementary Online Material). There were
88 European studies with 23 from the UK, 9 from Italy, 8 from
Spain, 8 from the Netherlands, 7 from Denmark, 7 from Finland, 5
from France, 5 from Norway, 3 from Switzerland, 3 from Sweden,
3 from Germany, 2 from Poland and 1 each from Austria, Belgium,
Romania, Greece and joint UK/Denmark. There were 18 studies
from Asia, with 5 from India, 4 from Japan, 4 from China, 2 from
Hong Kong, 2 from Malaysia and 1 from South Korea. There were
59 studies from the Americas, with 47 studies from the USA, 8
from Canada and 4 from Brazil. In addition, there were three from
Turkey, two from Israel, two from Australia, one each from New
Zealand, Saudi Arabia, Libya, South Africa and one unspecified.
148 were based in specialist care 148 (106 single site, 38
multisite and 4 unspecified), 21 were population based, 3 were set
in primary care, 3 database studies, 1 used hospital cancer registry
data and 1 was unspecified. Study design varied hugely, and it
included prospective and retrospective cohort studies, reviews of
medical records, database analyses, patient surveys and interviews.
The majority of the studies had retrospective designs.
Synthesis of main findings. The results of individual studies are
presented in Supplementary Online Material. No meta-analyses were
possible. The results are reported cancer by cancer. Studies are grouped
under ‘children teenagers and young adults’ where they reported at
least a significant proportion of participants aged o25 years.
Summaries for each cancer are reported in Table 1. Studies that
reported ‘positive’ associations (i.e., where there was evidence of
shorter intervals being associated with more favourable outcomes)
are presented first, followed by studies that reported no associations,
followed by those that reported ‘negative’ associations (i.e., where
there was evidence of shorter intervals being associated with less
favourable outcomes). In each section, studies reporting survival
outcomes (or mortality, but for simplicity just referred to as survival
in the table) are presented before those reporting stage and other
outcomes. A brief narrative for each cancer is provided below.
Symptom
onset
First seen in
primary care
Referral to
specialist
care
First seen in
specialist
care
Diagnosis Treatment
T1
T2
T3
T4
T5
T6
T7
T8
T9
T10
T11
T12
T13
T14
T15
T1 Time from symptom onset to first seen in primary care (‘symptom interval’)
T2 Time from symptom onset to referral to specialist care
T3 Time from onset to first seen in specialist care
T4 Time from symptom onset to diagnosis
T5 Time from symptom onset to treatment
T6 Time from first seen in primary care to referral to specialist care (‘referral interval’)
T7 Time from first seen in primary care to first seen in specialist care
T8 Time from first seen in primary care to diagnosis (‘diagnostic interval’) 
T9 Time from first seen in primary care to treatment 
T10 Time from referral to specialist care to first seen in specialist care
T11 Time from referral to specialist care to diagnosis
T12 Time from referral to specialist care to treatment
T13 Time from first seen in specialist care to diagnosis 
T14 Time from first seen in specialist care to treatment
T15 Time from diagnosis to treatment 
Figure 4. Definitions of time interval.
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For breast cancer, four studies reported positive associations,
including one of the studies that addressed the waiting time
paradox, and was able to demonstrate the effect of different
diagnostic intervals on mortality (Tørring et al, 2013). The
remainder reported no associations.
The lung studies had mixed findings, with similar numbers
of studies reporting positive, negative and no associations,
across a range of different time intervals. However, one of the
studies reporting a positive association with mortality for
diagnostic intervals addressed the waiting time paradox
(Tørring et al, 2013).
For colorectal cancer, although many studies reported no
associations, more studies reported a positive, rather than a
negative, association. Indeed, four studies addressing the waiting
time paradox were included, three of which reported a positive
association (Tørring et al, 2011, 2012, 2013) and one a negative
association (Pruitt et al, 2013). Of the upper gastrointestinal
cancers, most studies reported no association, and more reported a
Table 1. Summary results from narrative synthesis, by cancer
Positive association No association Negative association
Breast
Survival
Diagnostic interval (Tørring et al, 2013)
Treatment interval (Yun et al, 2012; Smith et al, 2013)
Survival
Treatment interval (Brazda et al, 2010; McLaughlin et al,
2012; Eastman et al, 2013; Mujar et al, 2013;
Redaniel et al, 2013; Sue et al, 2013)
Stage
Symptom onset to diagnosis (Ermiah et al, 2012; Warner
et al, 2012)
Stage
Treatment interval (Wright et al, 2010; Wagner et al, 2011)
Other outcomes
Treatment interval and risk of recurrence
(Eastman et al, 2013)
Lung
Survival
Diagnostic interval (Tørring et al, 2013)
Symptom onset to diagnosis (Maguire et al, 1994)
Survival
Symptom onset to treatment (Annakkaya et al, 2007)
Patient interval (Loh et al, 2006)
Diagnostic interval (Loh et al 2006; Pita-Fernandez et al,
2007; Skaug et al, 2011)
Treatment interval (Diaconescu et al, 2011; Yun et al, 2012)
Symptom onset to being seen in specialist care
(Garcia-Barcala, 2012)
Survival
Patient interval (Radzikowska et al, 2012)
Treatment interval (Gonzalez-Barcala et al, 2010)
Stage
Symptom onset to treatment (Christensen et al, 1997)
Treatment interval (Brocken et al, 2012; Murai et al, 2012)
Stage
Patient interval (Yilmaz et al, 2008; Tokuda et al, 2009)
Diagnostic interval(Pita-Fernandez et al, 2007;
Yilmaz et al, 2008)
Stage
Diagnostic interval (Gould et al, 2008)
Treatment interval (Salomaa et al, 2005)
Symptom onset to treatment (Myrdal et al, 2004)
Referral interval (Neal, 2007)
First seen in secondary care to diagnosis
(Brocken et al, 2012)
Other outcomes
Symptom onset to diagnosis and quality of life
(Mohan et al, 2006)
Gastric
Survival
Treatment interval (Yun et al, 2012)
Symptom onset to diagnosis (Maguire et al, 1994; Martin
et al, 1997; Windham et al, 2002; Arvanitakis et al, 2006)
Patient interval (Lim et al, 1974)
Primary care interval (Lim et al, 1974)
Survival
Symptom onset to diagnosis (Maconi et al, 2003)
Patient interval (Ziliotto et al, 1987)
Stage
Diagnostic interval (Fernandez et al, 2002)
Patient interval (Tokuda et al, 2009)
Stage
Diagnostic interval (Haugstvedt et al, 1991)
Oesophageal
Stage
Symptom onset to diagnosis (Martin et al, 1997)
Stage
Diagnostic interval (Fernandez et al, 2002)
Patient interval (Tokuda et al, 2009)
Stage
Symptom onset to treatment (Wang et al, 2008)
Gastro-oesophageal
Survival
Referral interval (Sharpe et al, 2010)
Other outcomes
Treatment interval and morbidity and in-hospital mortality
(Grotenhuis et al, 2010)
Pancreatic
Survival
Symptom onset to diagnosis (Gobbi et al, 2013)
Symptom onset to referral (Raptis et al, 2010)
Survival
Treatment interval (Yun et al, 2012)
Stage
Patient interval (Tokuda et al, 2009)
Other outcomes
Diagnostic interval and resectability (McLean et al, 2013)
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Table 1. ( Continued )
Positive association No association Negative association
Hepatocellular
Survival
Treatment interval (Singal et al, 2013)
Stage
Patient interval (Tokuda et al, 2009)
Colorectal
Survival
Diagnostic interval (Tørring et al, 2011, 2012, 2013)
Treatment interval (Gort et al, 2010–colon only; Yun et al,
2012–rectal only)
Survival
Diagnostic interval (Pruitt et al, 2013)
Referral interval (Zafar et al, 2011; Currie et al, 2012)
Symptom onset to treatment (Thompson et al, 2011)
First presentation to diagnosis (Singh et al, 2012)
Treatment interval (Roland et al, 2013)
Stage
Treatment interval (Guzman-Laura et al, 2011) colon
Referral interval (Valentin-Lopez et al, 2012)
Stage
Symptom onset to treatment (Terhaar sive Droste et al,
2010; Cerdan-Santacruz et al, 2011; Deng et al, 2012)
Referral interval (Ramsay et al, 2012)
Treatment interval (Van Hout et al, 2011)
Symptom onset to treatment (Van Hout et al, 2011)
Patient interval (Cerdan-Santacruz et al, 2011; Van Hout
et al, 2011)
Stage
Treatment interval (Guzman-Laura et al, 2011)
rectal
Other outcomes
Patient interval and satisfaction (Tomlinson et al, 2012)
Prostate
Survival
Diagnostic interval (Tørring et al, 2013)
Diagnosis to treatment (O’Brien et al, 2011)
Survival
Diagnosis to treatment (Korets et al, 2012; Sun et al, 2012)
Referral interval (Neal et al, 2007)
Stage
Diagnosis to treatment (Korets et al, 2012; Sun et al, 2012)
Patient interval (Tokuda et al, 2009)
Testicular
Survival
Patient interval (Hanson et al, 1993)
Diagnostic interval (Huyghe et al, 2007; Moul et al,
1990–non-seminoma only)
Symptom onset to treatment (Prout and Griffin, 1984;
Medical Research Council Working Party, Testicular
Tumours, 1985)
Survival
Patient interval (Fossa et al, 1981)
Symptom onset to treatment (Dieckmann et al, 1987)
Symptom onset to treatment Meffan et al, 1991)
Diagnostic interval (Moul et al, 1990; Harding et al, 1995–
seminoma only; Fossa et al, 1981)
Stage
Symptom onset to treatment (Ware et al, 1980; Wishnow
et al, 1990)
Patient interval (Ware et al, 1980; Chilvers et al, 1989)
Diagnostic interval (Bosl et al, 1981; Moul et al, 1990;
Huyghe et al, 2007–non-seminoma only)
Patient interval (Hanson et al, 1993)
Stage
Symptom onset to treatment (Dieckmann et al, 1987)
Symptom onset to treatment Meffan et al, 1991)
Diagnostic interval (Harding et al, 1995)
Other outcomes
Diagnostic interval and chance of complete remission
(Akdas et al, 1986); and response to treatment (Scher
et al, 1983)
Other outcomes
Symptom onset to treatment and relapse rate (Napier and
Rustin, 2000)
Renal
Stage
Patient interval (Tokuda et al, 2009)
Stage
Symptom onset to treatment (Holmang and
Johansson, 2006)
Bladder
Survival
Symptom onset to diagnosis (Hollenbeck et al, 2010)
Symptom onset to referral (Wallace et al, 2002)
Survival
Treatment interval (Gulliford et al, 1991)
Referral interval (Wallace et al, 2002)
Symptom onset to treatment (Mommsen et al, 1983)
Stage
Diagnostic interval (Liedberg et al, 2003)
Stage
Symptom onset to diagnosis (Maguire et al, 1994)
Patient interval (Tokuda et al, 2009)
Upper tract urothelial carcinoma
Survival
Diagnosis to treatment (Waldert et al, 2010; Sundi et al,
2012)
Stage
Diagnosis to treatment (Waldert et al, 2010)
Cervical
Survival
Treatment interval (Umezu et al, 2012)
Stage
Patient interval (Fruchter and Boyce, 1981)
Stage
Primary care interval (Fruchter and Boyce, 1981)
Patient interval (Tokuda et al, 2009)
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Table 1. ( Continued )
Positive association No association Negative association
Endometrial
Survival
Symptom onset to diagnosis (Menczer et al, 1995)
Survival
Referral to treatment interval (Crawford et al,
2002)
Diagnosis to treatment interval (Elit et al, 2013)
Stage
Symptom onset to diagnosis (Fruchter and Boyce, 1981;
Franceschi et al, 1983; Obermair et al, 1996)
Stage
Symptom onset to diagnosis (Pirog et al, 1997)
Patient interval (Tokuda et al, 2009)
Other outcomes
Symptom onset to treatment and quality of life and
satisfaction (Robinson et al, 2012)
Ovarian
Survival
Symptom onset to diagnosis (Nagle et al, 2011)
Referral interval (Neal et al, 2007)
Stage
Patient interval (Smith and Anderson, 1985; Tokuda et al,
2009)
Symptom onset to diagnosis (Fruchter and Boyce, 1981;
Menczer et al, 2009; Nagle et al, 2011)
Stage
Symptom onset to diagnosis (Lurie et al, 2010)
Other outcomes
Symptom onset to treatment and quality of life and
satisfaction (Robinson et al, 2012)
Head and neck
Survival
Patient interval (Koivunen et al, 2001–pharyngeal; Teppo
and Alho, 2008–pharyngeal and laryngeal cancers
(separately))
Diagnostic interval (Alho et al, 2006–head and neck
unspecified; Teppo et al, 2003–laryngeal; Teppo and
Alho, 2008–laryngeal)
Symptom onset to treatment (Hansen et al, 2004–
laryngeal)
Treatment interval (Sidler et al, 2010–nasopharyngeal)
Survival
Patient interval (Teppo et al, 2003–laryngeal; Teppo and
Alho, 2008–tongue)
Diagnostic interval (Seoane et al, 2010–oral; Teppo and
Alho, 2008–pharyngeal and tongue (separately); Koivunen
et al, 2001–pharyngeal)
Symptom onset to diagnosis (Wildt et al, 1995–oral)
Symptom onset to treatment (McGurk et al, 2005–head and
neck unspecified)
Treatment interval (Caudell et al, 2011–head and neck
unspecified; Brouha et al, 2000–laryngeal)
Stage
Patient interval (Kumar et al, 2001–oral; Brouha et al,
2005b–oral and pharyngeal cancer (separately); Lee et al,
1997–nasopharyngeal; Sheng et al, 2008–
nasopharyngeal; Tromp et al, 2005–head and neck
unspecified; Tokuda et al, 2009–head and neck
unspecified; Tromp et al, 2005–head and neck
unspecified)
Diagnostic interval (Allison et al, 1998–aerodigestive
tract; Al-Rajhi et al, 2009–nasopharyngeal)
Symptom onset to diagnosis (Allison et al, 1998–
aerodigestive tract; Al-Rajhi et al, 2009–nasopharyngeal)
Symptom onset to referral (Pitchers and Martin, 2006–
oropharyngeal)
Stage
Patient interval (Allison et al, 1998–upper aerodigestive
tract; Al-Rajhi et al, 2009–nasopharyngeal; Brouha et al,
2005a–laryngeal cancer; Wildt et al, 1995–oral; Teppo et al,
2009–vestibular schwannoma)
Diagnostic interval (Teppo et al, 2009–vestibular
schwannoma; Ho et al, 2004–oropharyngeal)
Symptom onset to diagnosis (Miziara et al, 1998–laryngeal;
Scott et al, 2005–oral)
Symptom onset to referral (Vernham and Crowther, 1994
head and neck unspecified)
Symptom onset to treatment (McGurk et al, 2005–head and
neck unspecified)
Other outcomes
Diagnostic interval and risk of recurrence (Teppo et al,
2005–laryngeal)
Other outcomes
Patient interval and risk of recurrence (Teppo et al, 2005–
laryngeal)
Brain/CNS
Other outcomes
Symptom onset to diagnosis and progressive
neurological deterioration (Balasa et al, 2012)
Melanoma
Survival
Patient interval (Temoshok et al, 1984, Montella et al,
2002)
Diagnostic interval (Temoshok et al, 1984; Metzger et al,
1998; Montella et al, 2002; Tørring et al, 2013)
Stage
Patient interval (Richards et al, 1999)
Symptom onset to diagnosis (Helsing et al, 1997)
Stage
Patient interval (Cassileth et al, 1982, Schmid-Wendtner
et al, 2002; Carli et al, 2003; Baade et al, 2006)
Diagnostic interval (Cassileth et al, 1982, Schmid-Wendtner
et al, 2002; Baade et al, 2006)
Symptom onset to diagnosis (Krige et al, 1991; Baade et al,
2006)
Non-melanoma skin
Stage
Patient interval (Tokuda et al, 2009)
Other outcomes
Symptom onset and presentation to specialist care and
increase in tumour size (Alam et al, 2011)
Other outcomes
Symptom onset to treatment and larger lesions (Renzi et al,
2010)
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negative, rather than a positive, association. For pancreatic cancer,
two of the five studies reported a positive association, one of which
addressed the waiting time paradox (Gobbi et al, 2013). The other
three studies reported no association.
Two of the prostate studies reported a positive association
for survival/mortality, one of which addressed the waiting time
paradox (Tørring et al, 2013); the others reported no association.
Two of the bladder studies reported a positive association;
the others reported no association. For testicular cancer, 15 studies
reported positive associations, and the remainder had no asso-
ciations.
For gynaecological cancers, of the four studies examining
cervix, one reported a positive association; the others reported
no association. For endometrial and ovarian cancers, there
were similar numbers of studies with positive, negative and
no associations. One of the endometrial studies that reported
a negative association addressed the waiting time paradox
(Elit et al, 2013).
Table 1. ( Continued )
Positive association No association Negative association
CTYA
Survival
Symptom onset to diagnosis (Marwaha et al, 2010b–
leukaemia; Ferrari et al, 2010–soft tissue sarcomas)
First seen in specialist care to diagnosis (Marwaha et al,
2010a–leukaemia)
Survival
Symptom onset to diagnosis (Kameda-Smith et al, 2013–
soft tissue sarcomas; Sethi et al, 2013–posterior fossa
tumours)
Diagnostic interval (Lins et al, 2012–leukaemia; Crawford
et al, 2009–primary spinal cord tumours)
Patient interval (Yang et al, 2009 –osteosarcoma)
Symptom onset to diagnosis (Brasme et al, 2012a, b–
medulloblastoma; Loh et al, 2012–paediatric solid tumours;
Butros et al, 2002–retinoblastoma)
Survival
Patient interval (Kukal et al, 2009–brain tumours)
First symptom to treatment (Erwenne and Franco,
1989–retinoblastoma)
Stage
Diagnostic interval (Wallach et al, 2006–retinoblastoma)
Stage
Patient interval (Yang et al, 2009 –osteosarcoma; Simpson
et al, 2005–Ewing’s sarcoma)
Symptom onset to diagnosis and eye loss (Butros et al,
2002–retinoblastoma)
Stage
Diagnostic interval (Crawford et al, 2009–primary
spinal cord tumours; Halperin et al, 2001–
medulloblastoma; Bacci et al, 1999–Ewing’s
sarcoma)
Other outcomes
Symptom onset to treatment and extra-ocular disease
(Erwenne and Franco, 1989–retinoblastoma)
Other outcomes
Patient interval and eye loss (Goddard and Kingston, 1999–
retinoblastoma)
Treatment interval and relapse rate (Wahl et al, 2012–
leukaemia)
Leukaemia
Survival
Diagnostic interval (Friese et al, 2011 (chronic lymphocytic))
Symptom onset to diagnosis (Prabhu et al, 1986 (chronic
myeloid))
Treatment interval (Bertoli et al, 2013 (acute myeloid))
Lymphoma
Survival
Symptom onset to diagnosis (Jacobi et al,2008 (follicular);
Maguire et al, 1994 (unspecified); Norum, 1995 (Hodgkin’s))
Survival
Symptom onset to diagnosis (Kim et al, 1995;
Foulc et al, 2003 (both Sezary syndrome))
Myeloma
Survival
Symptom onset to diagnosis (Kariyawasan et al, 2007)
Other outcomes
Symptom onset to diagnosis and complications at
diagnosis (Kariyawasan et al, 2007; Friese et al, 2009)
Connective tissue
Survival
Symptom onset to treatment (Ruka et al, 1988 (soft tissue
sarcoma))
Symptom onset to diagnosis (Saithna et al, 2008 (soft
tissue sarcoma))
Symptom onset to diagnosis (Nakamura et al, 2011 (soft
tissue sarcoma))
Survival
Symptom onset to diagnosis (Rougraff et al, 2007 (soft
tissue sarcoma); Wurtz et al, 1999 (osteosarcoma)
Stage
Symptom onset to diagnosis (Bacci et al, 2002
(osteosarcoma))
Carcinoid
Survival
Symptom onset to diagnosis (Toth-Fejel and Pommier,
2004)
Stage
Symptom onset to diagnosis (Toth-Fejel and Pommier,
2004)
Thyroid
Stage
Patient interval (Tokuda et al, 2009)
Multisite
Survival
Diagnostic interval (Tørring et al, 2013 (breast, lung,
colorectal, prostate and melanoma combined)
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For head and neck cancers (pharyngeal, laryngeal, oral and
others), there were a large number of studies and these were
equally divided between those reporting a positive association and
those reporting no association. No studies reported a negative
association.
For melanoma, eight studies reported positive associations, one
of which addressed the waiting time paradox (Tørring et al, 2013);
the remainder reported no associations. For non-melanoma skin,
two studies reported positive associations and one reported no
association.
There were a large number of studies covering the various
cancers in children, teenagers and young adults. The findings
of these were very mixed, with the biggest group showing
no associations, and smaller but similar number of studies
reporting both positive and negative associations. One of the ‘no
association’ studies addressed the waiting time paradox (Brasme
et al, 2012a, b).
For lymphoma, three studies reported no association or a
negative association. For leukaemia, the three studies reported no
associations. There were only two studies in myeloma, although
both of these reported positive outcomes. For the various
connective tissue cancers, three studies each reported a positive
association and no association. The other cancer groups (brain/
central nervous system, carcinoid, hepatocellular, renal, thyroid,
upper tract urothelial carcinoma and multisite) only had one or
two included studies.
DISCUSSION
Summary of main findings. This review is unique in that it has
assessed the literature for a range of different cancer types, and
hence we are able to make recommendations for policy practice
and research that are not limited to one cancer (or group of
cancers). The number of included studies in this review has shown
the importance of this question to patients, clinicians and
researchers. However, even within specific cancer types, there is
only moderate consensus as to the nature of any associations
between various time intervals in the diagnostic process and
clinical outcomes, with some studies showing no associations,
some studies showing better outcomes with shorter time intervals
and some the opposite. There are more reports of an association
between times to diagnosis and outcomes for breast, colorectal,
head and neck, testicular and melanoma, with reports from a
smaller number of studies for pancreatic, prostate and bladder
cancers. The time intervals in the studies varied, making it
impossible to draw consensus as to which intervals may be more,
or less, important. Moreover, the methodological quality of many
of these papers is mixed, despite a recent consensus paper on
design and reporting of such studies (Weller et al, 2012). There is
some evidence from papers published more recently that address
the waiting time paradox in their analyses (Tørring et al, 2011,
2012, 2013; Brasme et al, 2012a, b; Elit et al, 2013, Gobbi et al,
2013, Pruitt et al, 2013), with most, but not all, of these reporting
longer intervals being associated with poorer outcomes, particu-
larly mortality. This is important and begins to provide more
robust evidence about the relationship between time to diagnosis
and outcomes.
Findings within the context of the literature. The previous
cancer-specific reviews (Menczer, 2000; Jensen et al, 2002; Bell
et al, 2006; Fahmy et al, 2006; Ramos et al, 2007, 2008; Goy et al,
2009; Olsson et al, 2009; Thompson et al, 2010; Brasme et al,
2012a, b), with the exception of the breast cancer (Richards et al,
1999), and to a lesser extent head and neck (Seoane et al, 2012),
have been largely equivocal, probably because of the poor quality of
the included studies. Our findings are largely in keeping with these
reviews, although we have provided much more evidence than
previous reviews for testicular cancer (Bell et al, 2006) and head
and neck cancers (Goy et al, 2009). We have also identified more
recent and probably higher-quality papers providing better
evidence for colorectal cancer than covered in previous reviews
(Ramos et al, 2007, 2008; Thompson et al, 2010). We provide
review findings for the first time for many cancers. We are also
aware of further articles being published since the end date of our
review. For example, one of these replicated the methods of one of
the papers in our review (Tørring et al, 2011) on a sample of 958
colorectal cancers in Scotland, and reported that longer diagnostic
intervals did not adversely affect cancer outcomes (Murchie et al,
2014). Another has reported that time to diagnosis in 436 Ewing
tumours in France was not associated with metastasis, surgical
outcome or survival (Brasme et al, 2014). One of our main
findings, of the poor quality of reporting of time to diagnosis
studies, replicates the findings of a recent paediatric systematic
review (Launay et al, 2013).
Strengths and weaknesses. This is the largest and most compre-
hensive review in this field, and the first ‘all-cancer’ systematic
review. The huge heterogeneity in both the outcomes and the time
intervals used, within each cancer site, precluded meta-analyses.
Another systematic review has recently reported similar difficulty
in comparisons between studies (Lethaby et al, 2013). As
previously stated, the review only contains studies in colorectal
and breast cancer for 2010–13, and only these studies identified
during the second round of searches were assessed to determine
whether their analyses addressed the waiting time paradox.
Survival, or mortality, is the most objective outcomes for these
studies. However, many of the included studies in the review
reported stage, or some other proxy. This may explain why stage
and survival outcomes differ. Stage categorisation also varied, and
some of the studies may be affected by post-hoc upstaging.
A further problem with the literature is that of confounding
by indication. Symptoms of more advanced cancer are likely
to present differently and be investigated more promptly, as
are patients presenting with so-called ‘red-flag’ symptoms.
We were unable to assess for publication bias; indeed, if there
was any publication bias, we cannot predict in which direction
this would act.
Implications for policy, practice and research. Our main
conclusion from this review is that we believe that it is reasonable
to assume that efforts to expedite the diagnosis of symptomatic
cancer are likely to have benefits for patients in terms of earlier-
stage diagnosis, improved survival and improved quality of life.
The amount of benefit varies between cancers; at present, there is
more evidence for breast, colorectal, head and neck, testicular and
melanoma, with evidence from a smaller number of studies
for pancreatic, prostate and bladder cancers. There is either
insufficient evidence or equivocal findings in the other cancers.
The findings need replicating in using similar analytical methods,
ideally also to address how much of a difference expedited
diagnosis of different cancers would make on outcomes, and at
which points in the diagnostic journey matters most. Until we have
well-designed and well-analysed prospective studies to answer this
question, it is difficult to determine the likely effect of interventions
to reduce patient and diagnostic intervals on outcomes. This
knowledge would inform the development of targeted intervention
studies, to improve outcomes.
Hence, we recommend that policy, and clinicians, should
continue the current emphasis on expediting symptomatic
diagnosis, at least for most cancers. This can be achieved by
clinicians having a high index of suspicion of cancer, the use of
diagnostic technologies and rapid access to diagnostic investiga-
tions and fast-track pathways for assessment (Rubin et al, 2014).
Finally, we recommend the need for more high-quality research in
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the area for a number of reasons. First, we suspect that many
clinicians continue to believe that there are no associations between
time and clinical outcomes.
A considerable number of studies fail to address basic issues of
bias and thus equate the absence of evidence with evidence of
absence. Second, it is likely that more timely diagnosis may have a
greater or lesser impact between different cancers. This is
important to ascertain, because it will inform policy and practice.
We recommend, where possible, re-analysis of pooled (and similar)
data from some of the studies included in this review, and new
studies using linked data sets, across all cancers, such that similar
analyses can be conducted between cancers. We also recommend
that such studies should ideally focus on survival or mortality as
the outcome, as this is the ‘gold-standard’ outcome, although stage
is also a valuable end point. There is also a dearth of studies
reporting patient experience; we therefore recommend further
work that examined the relationship between patient perceptions
of ‘delay’ and quality of life and psychological outcomes. Suggested
key quality criteria for future studies are summarised in Box 1.
Other work should focus on the organisation and function of
health services, and subsequent time intervals and outcomes.
Furthermore, we recommend that, wherever possible, this work
should be conducted and reported in keeping within the
recommendations of the Aarhus Statement (Weller et al, 2012).
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